Statistical Sampling: an Underestimated Element of Process Validation?

In a recent FDA Warning Letter, the FDA criticized inadequate process validation for a semi-solid dosage form.  What exactly did the FDA find inadequate?

The validation studies were criticized for not reflecting inter- and intra-batch variability. In particular, there was criticism that the sampling was random. The viscosity sampling scheme does not lead to statistical confidence in process performance.

 In a second Process Performance Qualification (PPQ) study, the influence of a critical excipient on viscosity was to be shown. Again, the FDA criticized that no inter-batch variability was demonstrated. This is not surprising, since only one run was performed.  

As measures, the FDA requires:

  • a validation programme, starting with product development, the validation itself and the control/monitoring of the processes with regard to intra- and inter-batch variability
  • an equipment and premises qualification programme
  • a programme for Process Performance Qualification and Continued Process Verification measures.

You can find the entire Warning Letter on the FDA website.

Go back


Stay informed with the GMP Newsletters from ECA

GMP Newsletter

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, please click here.